The FDA issued a warning letter to Merck and Co. (Whitehouse Station, NJ) on April 28, citing numerous GMP violations at Merck’s vaccine production operations in West Point, PA.
The US Food and Drug Administration (FDA) issued a warning letter to Merck and Co. (Whitehouse Station, NJ) on April 28, citing numerous good manufacturing practice (GMP) violations at Merck’s vaccine production operations in West Point, PA. The FDA also requested a meeting with senior management at Merck to discuss the concerns cited in the warning letter.
Vaccines produced at the facility include the human papillomavirus vaccine Gardasil, and the combination measles, mumps, rubella, and chicken pox vaccine ProQuad.
Specific violations noted on the form include:
The FDA has stated that it has no reason to believe the problems affected the safety of Merck’s vaccines. The agency also said that the deficiencies would not affect the availability of the vaccines that are manufactured at the West Point facility, with the exception of PedvaxHIB and COMVAX, which were recalled in December 2007.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.